Skip to main content
ENDO 2026 Main banner

Adipose Tissue_Appetite_and Obesity

MON-703 - Comparative Effects of Enavogliflozin Versus Dapagliflozin on Adipokines and Leptin Sensitivity in Patients with Type 2 Diabetes: A Pooled Analysis of Phase 3 Trials

Monday, June 15, 2026
9:00 AM - 2:00 PM CT
Location: ENDOExpo; Poster Floor

    Co-Author(s)

  • YL

    Young Sang Lyu, MD.Phd.

    Associate professor
    CHOSUN UNIV/CENTRAL LIBR
    Gwangju, Republic of Korea

    • Abstract Poster Presenter(s)

  • KK

    Kyung-Soo Kim, MD, PhD

    Professor
    CHA Bundang Medical Center, CHA University School of Medicine
    Seongnam, South Korea

    • Submitting author(s)

  • CP

    Cheol-Young Park, MD.Phd.

    Kangbuk Samsung Hospital, Sungkyunkwan University
    Seoul, Kyonggi-do, Republic of Korea

    • Co-Author(s)

  • HL

    Hansol Lee, n/a

    Daewoong Pharmaceutical Co., Ltd
    Seoul, Kyonggi-do, Republic of Korea

  • SH

    Sangmo Hong, MD.Phd.

    Hanyang University Guri Hospital
    Seoul, Republic of Korea



Introduction: Adipokines are known to serve as a pathophysiological link between dysfunctional adipose tissue and cardiometabolic factors, but their relationship with sodium-glucose cotransporter 2 (SGLT2) inhibitors is not well established. This study evaluated the effects of enavogliflozin on adipokines and leptin sensitivity compared with dapagliflozin in patients with type 2 diabetes mellitus (T2DM).

Methods: This post-hoc analysis utilized pooled data from two randomized, double-blinded, active-controlled phase 3 trials. We evaluated 426 patients with T2DM who received either enavogliflozin 0.3 mg (n=214) or dapagliflozin 10 mg (n=212) for 24 weeks. Serum levels of adiponectin and leptin were measured at baseline and week 24. We analyzed changes in adipokines, the leptin/BMI ratio (a marker of leptin sensitivity), and their correlation with variables using spearman correlation analysis.

Results: Enavogliflozin demonstrated a significantly greater reduction in serum leptin levels compared with dapagliflozin (-1.24 vs. -0.78 µg/L, P = 0.043), whereas increases in adiponectin levels were comparable between groups (1.54 vs 1.21 mg/L, P = 0.306). The enavogliflozin group showed a greater trend toward improved leptin sensitivity compared to the dapagliflozin group (-0.06 vs -0.03, P = 0.058). Partial correlation analysis revealed that increases in blood ketone levels were negatively correlated with leptin levels.

Conclusion: Enavogliflozin demonstrated a superior reduction in serum leptin levels and a trend toward improved leptin sensitivity compared with dapagliflozin in patients with T2DM.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*